Toshiyuki Hikita

Dr. Toshiyuki Hikita


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2010 in Cephalalgia
Verified
Journal Article
Closed access
THToshiyuki Hikita
Toshiyuki Hikita
HKHiroko Kodama
Hiroko Kodama
SKSono Kaneko
Sono Kaneko
KAKaori Amakata
Kaori Amakata
KOKaori Ogita
Kaori Ogita
AKAkira Kikuchi
Akira Kikuchi
Background and objective: Cyclic vomiting syndrome (CVS) is associated with migraine. This study aimed to evaluate the efficacy of sumatriptan in treating CVS. Methods: Twelve patients were enrolled in this trial. Sumatriptan was administered either subcutaneously [(age × 4 + 20)/100×3mg] or by nasal spray (NS; 20 mg). Response to the treatment was classified as complete, effective, or noneffective. Results: Eleven patients, who presented with 35 attacks, were treated by subcutaneous injection of sumatriptan. The treatment was responsive in 19 attacks. The efficacy of sumatriptan was high in attacks that occurred in cases with a family history of migraine compared to those without (p = .0482). Five patients were treated with sumatriptan NS for six attacks. The treatment was completely responsive in two of six attacks. We observed no adverse effects associated with sumatriptan treatment in this trial. Conclusions: We conclude that sumatriptan has potential efficacy in treating of patients with CVS.

1 June 2009 in Brain and Development
Verified
Journal Article
Closed access
THToshiyuki Hikita
Toshiyuki Hikita
HKHiroko Kodama
Hiroko Kodama
NNNatsue Nakamoto
Natsue Nakamoto
FKFumiaya Kaga
Fumiaya Kaga
KAKaori Amakata
Kaori Amakata
YYYukishige Yanagawa
Yukishige Yanagawa

1 April 2016 in Pediatric Neurology
Verified
Journal Article
Closed access
THToshiyuki Hikita
Toshiyuki Hikita
HKHiroko Kodama
Hiroko Kodama
KOKaori Ogita
Kaori Ogita
SKSono Kaneko
Sono Kaneko
NNNatsue Nakamoto
Natsue Nakamoto
MMMasakazu Mimaki
Masakazu Mimaki

22 February 2012 in International Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
THToshiyuki Hikita
Toshiyuki Hikita
HHHiroyuki Hikita
Hiroyuki Hikita
FHFusako Hikita
Fusako Hikita
NHNaoko Hikita
Naoko Hikita
SHShizue Hikita
Shizue Hikita
The currently used antivirals in the treatment of influenza in Japan include amantadine, oseltamivir, zanamivir, laninamivir, and peramivir. We compared the efficacy of intravenous peramivir with that of other neuraminidase inhibitors for treating pediatric influenza. The present study included 223 influenza patients (18 years) who presented at the Hikita Pediatric Clinic between February and April 2011. We compared fever duration after starting treatment with antiviral drugs. Because inhalation drugs are difficult to use in <5-year-old patients and because of the potential adverse effects of oseltamivir in teenagers, we created two different age groups (<10-year-old group and 518-year-old group) to evaluate treatment results. In influenza A patients between 5 and 18 years old, the median fever duration after treatment with zanamivir was 2 days, compared with 1 day for peramivir (𝑃=0.0242). In influenza B patients between 5 and 18 years old, the median fever duration after treatment with laninamivir was 3 days, compared with 1 day for peramivir (𝑃=0.0097). We found no significant difference for any of the other combinations of drug/disease type/age groups. No adverse effects were observed with the antiviral drugs used. The results suggest that peramivir is very useful in pediatric influenza patients.

1 August 2011 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
THToshiyuki Hikita
Toshiyuki Hikita
TKTatsuro Kaminaga
Tatsuro Kaminaga
SWSuguru Wakita
Suguru Wakita
KOKaori Ogita
Kaori Ogita
HIHiroyuki Ikemoto
Hiroyuki Ikemoto
YYYukishige Yanagawa
Yukishige Yanagawa
Purpose: Kawasaki disease (KD) is an acute febrile disorder of unknown etiology. Brain single-photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI) help in detecting regional cerebral blood flow abnormalities and brain damage. The usefulness of SPECT and MRI in patients with KD was evaluated. Materials and Methods: All 22 patients with KD underwent brain SPECT using Tc-99m-hexamethyl propylene amine oxime from 6 days to 3 years after onset, and 8 patients underwent brain MRI. Of the 22 patients, 4 had neurologic symptoms. Case 1 showed prolonged apnea; case 2, prolonged disturbance of consciousness; and cases 3 and 4 generalized tonic-clonic seizures. Initial brain SPECT showed localized hypoperfusion in 4 and 13 patients with and without neurologic symptoms, respectively. Results: All patients with neurologic symptoms underwent follow-up SPECT; localized hypoperfusion was detected between 1- and 6-month follow-up in 3 of these patients. Six patients without neurologic symptoms underwent follow-up SPECT. Localized hypoperfusion was detected at approximately 1- to 11-month follow-up in 4 of these patients. Diffusion-weighted imaging revealed abnormal high-intensity areas in the corpus callosum in case 1. Case 2 showed a bilateral chronic subdural hematoma with decreased size and ischemic changes, and case 3 showed bilateral hippocampal atrophy and left hippocampal sclerosis. Conclusions: Because the occurrence of localized hypoperfusion is possibly not restricted to only the acute phase in KD, brain SPECT and MRI should also be performed in KD patients with neurologic symptoms.

11 March 2021 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
SOShoko Okitsu
Shoko Okitsu
PKPattara Khamrin
Pattara Khamrin
ATAksara Thongprachum
Aksara Thongprachum
THToshiyuki Hikita
Toshiyuki Hikita
KKKattareeya Kumthip
Kattareeya Kumthip
NMNihon University school of Medicine
Nihon University school of Medicine